60 Degrees Pharmaceuticals (SXTP) Enterprise Value (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Enterprise Value of -$3.4 million for Q1 2026, up 3.12% year-over-year from -$3.3 million in Q1 2025, and down 20.74% quarter-over-quarter from -$2.8 million in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Enterprise Value (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Enterprise Value for 5 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 3.12% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$3.4 million (up 3.12% YoY), while the FY2025 annual figure was -$2.8 million, up 45.46% from the prior year.
- Enterprise Value fell to -$3.4 million in Q1 2026 per SXTP's latest filing, from -$2.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$29993.0 in Q1 2023 and bottomed at -$5.2 million in Q4 2024.
- Historically, Enterprise Value has averaged -$2.4 million across 5 years, with a median of -$2.2 million in 2023.
- Annual changes were most pronounced in 2024 — Enterprise Value tumbled 9799.72% — and 2025, when it soared 45.46%.
- 60 Degrees Pharmaceuticals' Enterprise Value stood at -$837185.0 in 2022, then plunged by 164.52% to -$2.2 million in 2023, then slumped by 134.67% to -$5.2 million in 2024, then soared by 45.46% to -$2.8 million in 2025, then dropped by 20.74% to -$3.4 million in 2026.
- Business Quant data shows SXTP's Enterprise Value at -$3.4 million in Q1 2026, -$2.8 million in Q4 2025, and -$4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 2.12 Bn |
| 10 | 60 Degrees Pharmaceuticals | 3.05 Mn | 2.03 Mn | 56,798.00 | -1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.42 Mn |
| Dec 31, 2025 | -2.83 Mn |
| Sep 30, 2025 | -4.20 Mn |
| Jun 30, 2025 | -2.05 Mn |
| Mar 31, 2025 | -3.53 Mn |
| Dec 31, 2024 | -5.20 Mn |
| Sep 30, 2024 | -5.09 Mn |
| Jun 30, 2024 | -1.65 Mn |
| Mar 31, 2024 | -2.97 Mn |
| Dec 31, 2023 | -2.21 Mn |
| Sep 30, 2023 | -2.26 Mn |
| Jun 30, 2023 | -595,899.00 |
| Mar 31, 2023 | -29,993.00 |
| Dec 31, 2022 | -837,185.00 |
| Sep 30, 2022 | -439,393.00 |
| Jun 30, 2022 | -751,450.00 |